Novo Nordisk and Anthropic to team up on accelerating drug discovery through Claude

Novo Nordisk and Anthropic announced a collaboration intended to help Novo Nordisk speed up the development of new medicines and advance AI-driven software development.

The two companies will jointly tackle key drug discovery challenges identified by Novo Nordisk’s scientists and computational teams, build targeted solutions for specific scientific problems and workflows to support biological reasoning, and work to accelerate the discovery and development of new medicines.

Mike Doustdar, president and CEO of Novo Nordisk, said the partnership reflects the company’s ambition to become the world’s most AI-driven healthcare company, building on its existing AI work with other technology partners. He said joining forces with Anthropic will strengthen the company’s R&D organization and support its mission of bringing new, transformative health solutions to people living with chronic diseases. He added that AI can help boost productivity in R&D and shorten the path from research to a marketed product, but beyond that, AI tools can also open up entirely new scientific possibilities and support deeper reasoning and understanding of human biology and drug mechanisms.

As an initial step, Novo Nordisk will test Claude Science across specific R&D workflows, focusing on scientific problems where the combined capabilities of the two companies are expected to have the greatest impact.

Dario Amodei, co-founder and CEO of Anthropic, said AI’s growing capability carries the potential to compress a century’s worth of biological and medical breakthroughs into a single decade. He said giving leading researchers access to safe, capable, and trusted frontier models can shorten research timelines, improve outcomes, and lead to the discovery of medicines and treatments that meaningfully improve human life, adding that this is exactly what the collaboration with Novo Nordisk is designed to achieve.

Novo Nordisk will also draw on Anthropic’s frontier models to strengthen AI-driven software development, which the company views as a key enabler for scaling AI use across the organization.

The collaboration has been designed with strong data governance and human oversight built in, intended to help ensure AI is applied responsibly and in keeping with Novo Nordisk’s ethical and compliance standards.

---

---

Related Topics and Keywords

AI, Anthropic, biopharma news, chatgpt, claude, drug advancements, drug discovery, Novo Nordisk